TEVETEN (nda020738)- (EQ 300MG BASE,EQ 400MG BASE,EQ 600MG BASE)

Generic Name	EPROSARTAN MESYLATE	Innovator	ABBVIE
Dosage	EQ 300MG BASE,EQ 400MG BASE,EQ 600MG BASE
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2014-Aug-12	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	TEVETEN® is indicated for the treatment of hypertension.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 300MG BASE	**	**	-	-	-
EQ 400MG BASE	**	**	-	-	-
EQ 600MG BASE	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of TEVETEN